MCM
BMY.RT

MAI Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

MAI Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-11,182
Closed -$42K – 579
2020
Q1 		$42K Sell
11,182
-2,794
-20% -$9.2K ﹤0.01% 526
2019
Q4 		$42K Buy
+13,976
New +$36.3K ﹤0.01% 577

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MAI Capital Management's BMY.RT Position: Q2 2020 in Review

MAI Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q2 2020, closing a stake of 11,182 shares — an estimated $42K sold.

MAI Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 2 quarters. The position peaked at $42K in Q1 2020. 583 funds tracked by Wall St. Rank hold BMY.RT as of Q2 2020.

  • MAI Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q2 2020 after selling out during the quarter.
  • MAI Capital Management sold 11,182 Bristol-Myers Squibb Company Contingent Value Rights shares in Q2 2020, an estimated $42K.
  • MAI Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 2 quarters.
  • MAI Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $42K in Q1 2020.
  • 583 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q2 2020.

Based on MAI Capital Management's 13F filing for Q2 2020, filed 27 Jul 2020.